|
|
|
|
|
|
by toomanyrichies
1224 days ago
|
|
|
Reading these comments, I learned about human analog insulin and how it's considered more modern than older, off-patent versions. I was wondering about human analog insulin's patent status, and from here [1] I learned about the practice of patent ever-greening.[2] TL;DR: "Evergreening is any of various legal, business, and technological strategies by which producers (often pharmaceutical companies) extend the lifetime of their patents that are about to expire in order to retain revenues from them. Often the practice includes taking out new patents (for example over associated delivery systems or new pharmaceutical mixtures), or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law." A relevant quote from the Wikipedia article: "In one study of the prescription drug market, Feldman found that 78% of new patents associated with prescription drugs were for existing drugs." Depressing AF... 1. https://www.t1international.com/blog/2019/01/20/why-insulin-... 2. https://en.wikipedia.org/wiki/Evergreening |
|
|